Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Candel Therapeutics (CADL) Current Assets (2020 - 2025)

Candel Therapeutics' Current Assets history spans 4 years, with the latest figure at $36.8 million for Q4 2023.

  • On a quarterly basis, Current Assets fell 48.85% to $36.8 million in Q4 2023 year-over-year; TTM through Dec 2023 was $36.8 million, a 48.85% decrease, with the full-year FY2023 number at $36.8 million, down 48.85% from a year prior.
  • Current Assets hit $36.8 million in Q4 2023 for Candel Therapeutics, down from $45.1 million in the prior quarter.
  • Over the last five years, Current Assets for CADL hit a ceiling of $95.6 million in Q1 2022 and a floor of $24.4 million in Q2 2021.
  • Historically, Current Assets has averaged $63.9 million across 4 years, with a median of $66.9 million in 2022.
  • Biggest five-year swings in Current Assets: soared 257.51% in 2022 and later tumbled 48.85% in 2023.
  • Tracing CADL's Current Assets over 4 years: stood at $35.1 million in 2020, then soared by 141.69% to $84.9 million in 2021, then decreased by 15.3% to $71.9 million in 2022, then crashed by 48.85% to $36.8 million in 2023.
  • Business Quant data shows Current Assets for CADL at $36.8 million in Q4 2023, $45.1 million in Q3 2023, and $53.4 million in Q2 2023.